AxoGen, Inc.
LSE: 0HKD.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Equipment & Services
- CEO
- Michael D. Dale
- Employees
- 451
- Headquarters
- Alachua, United States
- IPO year
- 2018
- Market cap
- $2.0B
- Website
- https://www.axogeninc.com
Loading 0HKD…
Loading profile data…Frequently asked questions about 0HKD
What does AxoGen, Inc. (0HKD.L) do?
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgic...
Where does 0HKD.L trade?
AxoGen, Inc. (0HKD.L) trades on the London Stock Exchange.
What sector is 0HKD.L in?
AxoGen, Inc. (0HKD.L) operates in the Healthcare sector, specifically in the Medical - Equipment & Services industry.
Who is the CEO of AxoGen, Inc.?
Michael D. Dale is the chief executive officer of AxoGen, Inc. (0HKD.L).
Where is AxoGen, Inc. headquartered?
AxoGen, Inc. is headquartered in United States.
Does 0HKD.L pay a dividend?
AxoGen, Inc. (0HKD.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0HKD.L go public?
AxoGen, Inc. (0HKD.L) completed its initial public offering in 2018.